Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
LSTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.87 - $4.20
Previous CloseN/A
Volume45.87K
Average Volume (3M)22.52K
Market Cap
$21.63M
Enterprise Value$2.77M
Total Cash (Recent Filing)$21.97M
Total Debt (Recent Filing)$47.00K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 06, 2025EPS Estimate
-0.54Last Dividend Ex-Date
Oct 28, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding8,755,948
10 Day Avg. Volume20,945
30 Day Avg. Volume22,520
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit2.94
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$23.50Price Target Upside851.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEncouraging preliminary results from Cohort B of the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma.
Clinical TrialsEnrollment in the 1L cohort was completed nearly 6 months ahead of initial projections, accelerating the anticipated topline data readout to 4Q25.
Financial PerformanceLisata announced 2Q25 financial results, posting EPS of ($0.54) compared to our estimate of ($0.66) and consensus of ($0.65).
Bears Say
EarningsThe company ended the quarter with approximately $22 million in cash, which management believes can cover expenses for all ongoing and proposed trials with runway into 4Q26.
Lisata Therapeutics News
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $1.87 and its highest was $4.20 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $21.63M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 38 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.11.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics pays a Notavailable dividend of $0.31 which represents an annual dividend yield of N/A. See more information on Lisata Therapeutics dividends here
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -0.54.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 8,755,948 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in LSTA
Lisata Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.50 (851.42% Upside)
$23.50 (851.42% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.5%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.33%
12-Months-Change
Fundamentals
Return on Equity
-63.84%
Trailing 12-Months
Asset Growth
-40.90%
Trailing 12-Months
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
LSTA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant achievements in strategic partnerships and promising clinical results for certepetide. Financial management appears strong with reduced costs and an extended cash runway. However, the company's minimal current revenue and dependency on future funding are concerning. Despite these challenges, the highlights slightly outweigh the lowlights, suggesting cautious optimism.View all LSTA earnings summariesLSTA Stock 12 Month Forecast
Average Price Target
$23.50
▲(851.42% Upside)
Technical Analysis
ProMIS Neurosciences
―
MindWalk Holdings
―
BioAtla
―
Elevation Oncology
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
7.92% Insiders
3.60% Mutual Funds
2.40% Other Institutional Investors
83.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---